AL amyloidosis is not technically classified as cancer, but it behaves like one in important ways. It arises from the same type of abnormal cells that cause multiple myeloma, a blood cancer, and it’s treated with many of the same chemotherapy drugs. The distinction matters medically, but in practical terms, your experience as a patient will look a lot like cancer treatment.
Why It’s Not Classified as Cancer
In cancer, the core problem is uncontrolled cell growth that invades and destroys tissue. In AL amyloidosis, the damage comes from a different mechanism. Abnormal plasma cells in your bone marrow produce excess fragments of antibody proteins called light chains. These light chains misfold and clump together into stiff, insoluble fibers called amyloid, which deposit in organs and gradually shut them down. The plasma cells themselves are typically present in smaller numbers than in a full-blown blood cancer like myeloma.
So the distinction comes down to what’s doing the harm. In myeloma, the cancer cells themselves are the main threat. In AL amyloidosis, the real danger is the toxic protein those cells produce. You can have a relatively small population of abnormal cells and still develop life-threatening organ damage because even a modest amount of misfolded protein accumulates over time.
The Overlap With Multiple Myeloma
AL amyloidosis sits on a spectrum of plasma cell disorders that also includes myeloma. Conventionally, about 10% of AL amyloidosis patients are thought to have coexisting myeloma. But more sensitive testing methods suggest the overlap may be much higher. One study using immunohistochemistry on bone marrow samples found that 84% of AL amyloidosis patients met criteria for concurrent myeloma based on plasma cell counts, a striking figure that has prompted researchers to question whether the two conditions are as distinct as previously assumed.
This overlap explains why AL amyloidosis is often managed by the same oncologists and hematologists who treat blood cancers. Its ICD-10 medical code doesn’t place it in the neoplasm (tumor) category, but it’s grouped with plasma cell dyscrasias, a family of disorders involving these same clonal cells.
How It Damages the Body
The heart and kidneys are the organs most commonly affected. Amyloid deposits stiffen the heart muscle, leading to progressive heart failure and abnormal heart rhythms. In the kidneys, deposits cause protein to leak into the urine, which can progress to severe swelling in the legs, high cholesterol, increased infection risk, and eventually kidney failure.
Early symptoms are frustratingly vague: fatigue, unintentional weight loss, numbness or tingling in the hands and feet, and shortness of breath. Some people develop an enlarged tongue, which is one of the more distinctive signs. Because these symptoms mimic so many other conditions, diagnosis is often delayed, and by the time AL amyloidosis is confirmed, irreversible organ damage may already be present.
How It’s Diagnosed
Confirming AL amyloidosis requires four things: evidence of a systemic syndrome affecting one or more organs, a tissue biopsy showing amyloid deposits, signs of an abnormal plasma cell population, and protein typing to confirm the deposits are made of light chains specifically. That last step is critical because other types of amyloidosis exist, and treatments differ significantly.
Biopsies are typically taken from bone marrow or abdominal fat. If heart involvement is suspected but imaging and blood tests give conflicting results, a direct biopsy of the heart muscle may be needed. Once amyloid is found, the deposits are typed using techniques like mass spectrometry to identify exactly which protein is involved. This matters because a common age-related condition called MGUS produces similar blood markers, and misidentifying the amyloid type could lead to the wrong treatment entirely.
Treatment Looks Like Cancer Therapy
Regardless of whether AL amyloidosis carries the “cancer” label, the treatments are borrowed directly from oncology. The only FDA-approved first-line regimen is a four-drug combination: a targeted antibody (daratumumab) paired with two chemotherapy agents and a steroid. The goal is to wipe out the abnormal plasma cells so they stop producing the toxic light chains. Most patients go through four to six cycles of this regimen, aiming for a deep reduction in the abnormal protein levels.
If the disease comes back or doesn’t respond, doctors have several options depending on what was used initially. Alternative chemotherapy agents, drugs that modify the immune system, and newer approaches like CAR-T cell therapy (where your own immune cells are engineered to attack the abnormal plasma cells) are all in the treatment toolkit. For patients with a specific genetic change in their plasma cells, a targeted drug called venetoclax may work better than standard chemotherapy.
Eligible patients may also undergo stem cell transplant, which involves high-dose chemotherapy followed by an infusion of your own previously collected stem cells to rebuild the bone marrow. This is one of the most aggressive treatment options available and mirrors what’s done for blood cancers.
Prognosis Depends on Organ Damage
Survival in AL amyloidosis is staged primarily by how much damage has already occurred to the heart, measured through cardiac biomarkers in the blood. The revised Mayo Clinic staging system breaks patients into four stages with dramatically different outcomes:
- Stage I: Median survival of about 94 months (nearly 8 years)
- Stage II: Median survival of about 40 months (just over 3 years)
- Stage III: Median survival of about 14 months
- Stage IV: Median survival of about 6 months
These numbers reflect the reality that heart involvement is the primary driver of mortality. Patients caught early, before significant cardiac damage, have a much better outlook, especially with newer treatment regimens that achieve deeper and faster responses than older therapies. This is why the vague early symptoms are so consequential. The earlier the abnormal plasma cells are stopped, the less amyloid accumulates, and the more organ function can be preserved or even partially recovered.
The Label Matters Less Than You Think
If you or someone you know has been diagnosed with AL amyloidosis, the question of whether it “counts” as cancer is understandable but somewhat academic. You’ll likely be treated at a cancer center, by oncologists, with chemotherapy and possibly a stem cell transplant. Insurance coverage, disability considerations, and clinical trial access often follow cancer-adjacent pathways. The biology is a plasma cell disorder that produces a toxic protein rather than a growing tumor, but the lived experience of treatment, the urgency of early intervention, and the seriousness of the prognosis are comparable to what cancer patients face.